By Associate Professor Yeh Chen Lee

Journal articles

Symons R; Heath F; Duggan J; Bui KT; Byun L; Friedlander M; Lee YC, 2024, 'Rates of paclitaxel hypersensitivity reactions using a modified Markman’s infusion protocol as primary prophylaxis', Supportive Care in Cancer, 32, pp. 292, http://dx.doi.org/10.1007/s00520-024-08460-z

Campbell R; King MT; Stockler MR; Lee YC; Roncolato FT; Friedlander ML, 2023, 'Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice', Patient Related Outcome Measures, 14, pp. 111 - 126, http://dx.doi.org/10.2147/prom.s297301

Gonzalez-Ochoa E; Milosevic M; Corr B; Abbruzzese JL; Girda E; Miller RW; Croke J; Mackay H; Lee YC; Bowering V; Ramsahai J; Wang L; D'Souza A; Kunos CA; Oza AM; Lheureux S, 2023, 'A phase i study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers', International Journal of Gynecological Cancer, 33, pp. 1208 - 1214, http://dx.doi.org/10.1136/ijgc-2023-004491

Mileshkin LR; Narayan K; Gaffney DK; Barnes EH; Lee YC; Monk BJ; Stockler MR, 2023, 'Adjuvant chemotherapy for locally advanced cervical cancer – Authors’ reply', Lancet Oncology, 24, pp. e290, http://dx.doi.org/10.1016/S1470-2045(23)00294-2

Lindemann K; Liland H; Donner MS; Brew S; Lee YC; Vistad I; Berge Nilsen E; Lombard JM; Mirza MR; Madsen K; Hansson AM; Andrews J; Campbell R; Davis AJ, 2023, 'GCIG SB-001/NSGO-CTU-PEACE/ANZGOG 1923/2020: Palliation in gynae-oncology—Patients' expectations and assessment of care.', Journal of Clinical Oncology, 41, pp. TPS5635 - TPS5635, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps5635

Buchanan DD; Mahmood K; Georgeson P; Walker R; Robledo K; Cummins MM; Spurdle AB; Smith DS; Joo E; Clendenning M; Como J; Preston S; Yip S; Andrews J; Kok PS; Lee YC; Stockler MR; Mileshkin LR; Antill YC, 2023, 'The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601).', Journal of Clinical Oncology, 41, pp. 5604 - 5604, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5604

Mileshkin LR; Moore KN; Barnes EH; Gebski V; Narayan K; King MT; Bradshaw N; Lee YC; Diamante K; Fyles AW; Small W; Gaffney DK; Khaw P; Brooks S; Thompson JS; Huh WK; Mathews CA; Buck M; Suder A; Lad TE; Barani IJ; Holschneider CH; Van Dyk S; Quinn M; Rischin D; Monk BJ; Stockler MR, 2023, 'Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial', Lancet Oncology, 24, pp. 468 - 482, http://dx.doi.org/10.1016/S1470-2045(23)00147-X

Pitiyarachchi O; Lee YC; Sim HW; Srirangan S; Mapagu C; Kirk J; Harnett PR; Balleine RL; Bowtell DDL; Samimi G; Brand AH; Marsh DJ; Beale P; Anderson L; Bouantoun N; Provan P; Ramus SJ; DeFazio A; Friedlander M, 2023, 'Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma', Translational Oncology, 31, http://dx.doi.org/10.1016/j.tranon.2023.101638

Hayes S; Obermair A; Mileshkin L; Davis A; Gordon LG; Eakin E; Janda M; Beesley VL; Barnes EH; Spence RR; Sandler C; Jones T; Vagenas D; Webb P; Andrews J; Brand A; Lee YC; Friedlander M; Pumpa K; O'Neille H; Williams M; Stockler M, 2023, 'Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: Design and implementation of a randomised controlled trial', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2022-067925

Cohen PA; Webb PM; King M; Obermair A; Gebski V; Butow P; Morton R; Lawson W; Yates P; Campbell R; Meniawy T; McMullen M; Dean A; Goh J; McNally O; Mileshkin L; Beale P; Beach R; Hill J; Dixon C; Hegarty S; Codde J; Ives A; Lee YC; Brand A; Mellon A; Bilic S; Black I; Jeffares S; Friedlander M, 2023, 'Getting the MOST out of follow-up: A randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer', International Journal of Gynecological Cancer, http://dx.doi.org/10.1136/ijgc-2021-002999

Jivraj N; Lee YC; Tinker L; Bowering V; Ferguson SE; Croke J; Karakasis K; Chawla T; Lau J; Ng P; Dhar P; Shlomovitz E; Buchanan S; Dhani N; Oza AM; Stuart-Mcewan T; Lheureux S, 2023, 'Management of Malignant Bowel Obstruction: An Innovative Proactive Outpatient Nurse-Led Model of Care for Patients With Advanced Gynecologic Cancer', Journal of Nursing Care Quality, 38, pp. 69 - 75, http://dx.doi.org/10.1097/NCQ.0000000000000661

Smith D; Robledo KP; Yip S; Cummins MM; Kok PS; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Spurdle AB; Andrews J; Stockler MR; Mileshkin L; Antill Y, 2023, 'Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)', Cancers, 15, http://dx.doi.org/10.3390/cancers15010254

Colombo N; Harano K; Hudson E; Galli F; Antill Y; Choi CH; Rabaglio M; Marmé F; Petru E; Lai C-H; Biagioli E; Madrid LF; Takehara K; Allan K; Lee YC; Piovano E; Zamagni C; Tasca G; Ferrero A; Ginesta MPB, 2023, 'LBA40 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma', Annals of Oncology, 34, pp. s1281 - s1282, http://dx.doi.org/10.1016/j.annonc.2023.10.034

Friedlander M; Lee YC; Tew WP, 2023, 'Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data.', American Society of Clinical Oncology Educational Book, 43, pp. e390876, http://dx.doi.org/10.1200/edbk_390876

Woopen H; Sehouli J; Davis A; Lee YC; Cohen PA; Ferrero A; Gleeson N; Jhingran A; Kajimoto Y; Mayadev J; Barretina-Ginesta MP; Sundar S; Suzuki N; van Dorst E; Joly F, 2022, 'Erratum to “GCIG-Consensus guideline for long-term survivorship in gynecologic cancer: A position paper from the Gynecologic Cancer InterGroup (GCIG) symptom benefit committee” [Cancer Treatm. Rev. 107 (2022) 102396] (Cancer Treatment Reviews (2022) 107, (S0305737222000603), (10.1016/j.ctrv.2022.102396))', Cancer Treatment Reviews, 109, http://dx.doi.org/10.1016/j.ctrv.2022.102431

Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky MC; Diamante K; Stockler MR; Friedlander ML, 2022, 'Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study', Obstetrical and Gynecological Survey, 77, pp. 531 - 533, http://dx.doi.org/10.1097/OGX.0000000000001075

Campbell R; Costa DSJ; Stockler MR; Lee YC; Ledermann JA; Berton D; Sehouli J; Roncolato FT; Connell RO; Okamoto A; Bryce J; Oza AM; Avall-Lundqvist E; Berek JS; Lanceley A; Joly F; Hilpert F; Feeney A; Kaminsky MC; Diamante K; Friedlander ML; King MT, 2022, 'Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer', Gynecologic Oncology, 166, pp. 254 - 262, http://dx.doi.org/10.1016/j.ygyno.2022.05.024

Sivakumaran T; Krasovitsky M; Freimund A; Lee YC; Webber K; So J; Norris C; Friedlander M; Mileshkin L; Au-Yeung G, 2022, 'Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients', International Journal of Gynecological Cancer, 32, pp. 906 - 912, http://dx.doi.org/10.1136/ijgc-2021-003009

Delahunty R; Nguyen L; Craig S; Creighton B; Ariyaratne D; Garsed DW; Christie E; Fereday S; Andrews L; Lewis A; Limb S; Pandey A; Hendley J; Traficante N; Carvajal N; Spurdle AB; Thompson B; Parsons MT; Beshay V; Volcheck M; Semple T; Lupat R; Doig K; Yu J; Chen XQ; Marsh A; Love C; Bilic S; Beilin M; Nichols CB; Greer C; Lee YC; Gerty S; Gill L; Newton E; Howard J; Williams R; Norris C; Stephens AN; Tutty E; Smyth C; O'connell S; Jobling T; Stewart CJR; Tan A; Fox SB; Pachter N; Li J; Ellul J; Mir Arnau G; Young MA; Gordon L; Forrest L; Harris M; Livingstone K; Hill J; Chenevix-Trench G; Cohen PA; Webb PM; Friedlander M; James P; Bowtell D; Alsop K, 2022, 'TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members', Journal of Clinical Oncology, 40, pp. 2036 - 2047, http://dx.doi.org/10.1200/JCO.21.02108

Woopen H; Sehouli J; Davis A; Lee YC; Cohen PA; Ferrero A; Gleeson N; Jhingran A; Kajimoto Y; Mayadev J; Barretina-Ginesta MP; Sundar S; Suzuki N; van Dorst E; Joly F, 2022, 'GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee', Cancer Treatment Reviews, 107, http://dx.doi.org/10.1016/j.ctrv.2022.102396

Krasovitsky M; Lee YC; Sim HW; Chawla T; Moore H; Moses D; Baker L; Mandel C; Kielar A; Hartery A; O'Malley M; Friedlander M; Oza AM; Wang L; Lheureux S; Wilson M, 2022, 'Interobserver and intraobserver variability of RECIST assessment in ovarian cancer', International Journal of Gynecological Cancer, 32, pp. 656 - 661, http://dx.doi.org/10.1136/ijgc-2021-003319

Farrell R; Burling M; Lee YC; Pather S; Robledo K; Mercieca-Bebber R; Stockler M, 2022, 'Clinical trial protocol for HyNOVA: Hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage iii epithelial ovarian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020)', Journal of Gynecologic Oncology, 33, http://dx.doi.org/10.3802/JGO.2022.33.E1

Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky M-C; Diamante K; Stockler MR; Friedlander ML, 2022, 'Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study', Obstetrical & Gynecological Survey, 77, pp. 531 - 533, http://dx.doi.org/10.1097/ogx.0000000000001075

Obermair A; Beale P; Scott CL; Beshay V; Kichenadasse G; Simcock B; Nicklin J; Lee YC; Cohen P; Meniawy T, 2021, 'Insights into ovarian cancer care: Report from the Anzgog ovarian cancer webinar series 2020', Journal of Gynecologic Oncology, 32, http://dx.doi.org/10.3802/JGO.2021.32.E95

Werner B; Yuwono N; Duggan J; Liu D; David C; Srirangan S; Provan P; DeFazio A; Arora V; Farrell R; Lee YC; Warton K; Ford C, 2021, 'Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer', Gynecologic Oncology, 162, pp. 720 - 727, http://dx.doi.org/10.1016/j.ygyno.2021.06.028

Mileshkin LR; Moore KN; Barnes E; Gebski V; Narayan K; Bradshaw N; Lee YC; Diamante K; Fyles AW; Small W; Gaffney DK; Khaw P; Brooks S; Thompson JS; Huh WK; Carlson M; Mathews CA; Rischin D; Stockler MR; Monk BJ, 2021, 'Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).', Journal of Clinical Oncology, 39, pp. lba3 - lba3, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.lba3

Antill Y; Kok PS; Robledo K; Yip S; Cummins M; Smith D; Spurdle A; Barnes E; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Andrews J; Stockler MR; Mileshkin L, 2021, 'Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial', Journal for Immunotherapy of Cancer, 9, http://dx.doi.org/10.1136/jitc-2020-002255

Madariaga A; Garg S; Bruce JP; Thiryayi S; Mandilaras V; Rath P; Oza AM; Dhani NC; Cescon DW; Lee YC; Chen E; Wang L; Clarke B; Lheureux S, 2020, 'Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer', Gynecologic Oncology, 159, pp. 539 - 545, http://dx.doi.org/10.1016/j.ygyno.2020.08.032

Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM, 2020, 'EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib plus Olaparib for Ovarian Cancer after PARP Inhibition Progression', Clinical Cancer Research, 26, pp. 4206 - 4215, http://dx.doi.org/10.1158/1078-0432.CCR-19-4121

Cusimano MC; Sajewycz K; Nelson M; Jivraj N; Lee YC; Bowering V; Oza A; Lheureux S; Ferguson SE, 2020, 'Supported self-management as a model for end-of-life care in the setting of malignant bowel obstruction: A qualitative study', Gynecologic Oncology, 157, pp. 745 - 753, http://dx.doi.org/10.1016/j.ygyno.2020.03.009

Liu SL; Lee YC; Jivraj N; Bowering V; Wang L; Bhat G; Madariaga A; Kasherman L; Nathwani K; Tesfu A; Lee S; Ferguson SE; Croke JM; O'Brien C; Lau J; Chawla T; Schlomovitz E; Oza AM; Lheureux S, 2020, 'Risk stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program for women with gynecological cancers: Preliminary results from a prospective single-center study.', Journal of Clinical Oncology, 38, pp. 6062 - 6062, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6062

Lee YC; Wang L; Kohn EC; Rubinstein L; Ivy SP; Harris PJ; Lheureux S, 2020, 'Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancer', Cancer, 126, pp. 2139 - 2145, http://dx.doi.org/10.1002/cncr.32783

Madariaga A; Garg S; Bruce J; Rath P; Mandilaras V; Thiryayi S; Oza AM; Dhani N; Lee YC; Clarke BA; Lheureux S, 2020, 'Biomarkers of outcome with weekly paclitaxel in platinum-resistant high-grade serous or endometrioid ovarian carcinoma', Gynecologic Oncology, 159, pp. 149 - 149, http://dx.doi.org/10.1016/j.ygyno.2020.05.207

Bhat G; Jivraj N; Oza AM; Dhani N; Lee YC; Madariaga A; Kasherman L; McMullen M; Liu S; Bowering V; Ferguson SE; Croke J; Lheureux S, 2020, 'Proactive inter-professional program to manage malignant bowel obstruction (MBO) in women with advanced gynecological cancer: Improving quality of care, education and awareness of malignant bowel obstruction among patients and health care providers', Gynecologic Oncology, 159, pp. 55 - 56, http://dx.doi.org/10.1016/j.ygyno.2020.06.116

Cusimano MC; Sajewycz K; Nelson M; Jivraj N; Bowering V; Lee YC; Lheureux S; Ferguson SE, 2020, 'Supported self-management as an innovative model of care for advanced gynecologic cancer patients with malignant bowel obstruction: A qualitative study', Gynecologic Oncology, 159, pp. 314 - 315, http://dx.doi.org/10.1016/j.ygyno.2020.05.568

Bonilla L; Oza AM; Lheureux S; Saibil S; Chen S; Lee YC; Gray D; Colombo I; Madariaga A; Dhani NC; Bhat G; Bowering V; Garg S; Yokom D; Cyriac SL; Butler MO, 2019, 'Clinical outcome of sequential chemotherapy after immune checkpoint inhibitors in advanced ovarian cancer.', Journal of Clinical Oncology, 37, pp. 5580 - 5580, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5580

Lheureux S; Oaknin A; Garg S; Bruce J; Dhani NC; Madariaga A; Bonilla L; Lee YC; Colombo I; Bhat G; Bowering V; White J; Accardi S; Tan S; Braunstein M; Karakasis K; Liu ZA; Pugh TJ; Oza AM, 2019, 'Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.', Journal of Clinical Oncology, 37, pp. 5521 - 5521, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5521

Bhat G; Madariaga A; Bonilla L; Lee YC; Dhani NC; Jivraj N; Chawla T; Buchanan S; Ferguson S; O'Brien C; Dhar P; Shlomovitz E; Lau J; Mulumba S; Karakasis K; Chllamma M; Oza AM; Lheureux S, 2019, 'Implementation of malignant bowel obstruction multidisciplinary case conferences (MCCs) to improve clinical decision making in malignant bowel obstruction (MBO) in gynecologic oncology.', Journal of Clinical Oncology, 37, pp. e18322 - e18322, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18322

Lee YC; Jivraj N; Wang L; Chawla T; Lau J; Croke J; Allard JP; Stuart-McEwan T; Nathwani K; Bowering V; Karakasis K; O’Brien C; Shlomovitz E; Ferguson SE; Buchanan S; Ng P; Cyriac S; Tinker L; Dhani N; Oza AM; Lheureux S, 2019, 'Optimizing the care of malignant bowel obstruction in patients with advanced gynecologic cancer', Journal of Oncology Practice, 15, pp. e1066 - e1075, http://dx.doi.org/10.1200/JOP.18.00793

Lee YC; Davis A, 2019, 'To treat or not to treat', JNCI Cancer Spectrum, 3, pp. pkz023, http://dx.doi.org/10.1093/jncics/pkz023

Thomas R; Roy B; Maldonado F; Lee YC, 2019, 'Management of Malignant Pleural Effusions—What Is New', Seminars in Respiratory and Critical Care Medicine, 40, pp. 323 - 339, http://dx.doi.org/10.1055/s-0039-1698285

Kwan B, 2018, 'Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial', The Lancet Respiratory Medicine, 6, pp. 671 - 680, http://dx.doi.org/10.1016/S2213-2600(18)30288-1

Cyriac SL; Wilson MK; Bowering VL; Hunt W; Gutierrez D; Lee YC; Colombo I; Bonilla L; Speers V; Ghai S; Dhani NC; Butler MO; Oza AM; Lheureux S, 2018, 'Prospective assessment of tumor biopsies as part of clinical trials: Patients’ (pts) perspectives.', Journal of Clinical Oncology, 36, pp. 2539 - 2539, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.2539

Lee YC; Wang L; Kohn EC; Rubinstein L; Ivy SP; Harris P; Lheureux S, 2018, 'Toxicity profile of patients with gynecological cancers (Gyne) enrolled in phase I trials.', Journal of Clinical Oncology, 36, pp. 5572 - 5572, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.5572

Lee YC; Jivraj N; O'brien C; Chawla T; Shlomovitz E; Buchanan S; Lau J; Croke J; Allard JP; Dhar P; Laframboise S; Ferguson SE; Dhani N; Butler M; Ng P; Stuart-Mcewan T; Savage P; Tinker L; Oza AM; Lheureux S, 2018, 'Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective', Obstetrics and Gynecology International, 2018, pp. 1867238, http://dx.doi.org/10.1155/2018/1867238

Lee YC; Jivraj N; O'Brien C; Lau J; Chawla T; Shlomovitz E; Buchanan S; Croke J; Allard JP; Dhar P; Laframboise S; Ferguson SE; Dhani NC; Butler MO; Ng P; Stuart-McEwan T; Savage P; Tinker LM; Oza AM; Lheureux S, 2017, 'Novel malignant bowel obstruction (MBO) management program for women with advanced gynecological cancer.', Journal of Clinical Oncology, 35, pp. 158 - 158, http://dx.doi.org/10.1200/jco.2017.35.31_suppl.158

Lee YC; Bressel M; Grant P; Russell P; Smith C; Picken S; Camm S; Kiely BE; Milne RL; McLachlan SA; Hickey M; Friedlander ML; Hopper JL; Phillips KA, 2017, 'Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer', Familial Cancer, 16, pp. 461 - 469, http://dx.doi.org/10.1007/s10689-017-9977-x

Lee YC; Milne RL; Lheureux S; Friedlander M; McLachlan SA; Martin KL; Bernardini MQ; Smith C; Picken S; Nesci S; Hopper JL; Phillips KA, 2017, 'Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers', European Journal of Cancer, 84, pp. 114 - 120, http://dx.doi.org/10.1016/j.ejca.2017.07.004

Lee YC; Kroon R; Koczwara B; Haines I; Francis K; Millward M; Kefford R; Olver I; Mileshkin L, 2017, 'Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia', Internal Medicine Journal, 47, pp. 888 - 893, http://dx.doi.org/10.1111/imj.13482

Lee YC; Lheureux S; Jivraj N; O'Brien C; Laframboise S; Tinker LM; Patel T; Stuart-McEwan T; Savage P; Easson AM; Croke J; Lau J; Shlomovitz E; Chawla T; Allard J; Buchanan S; Ng P; Karakasis K; Oza AM, 2017, 'Risk-stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program for women with advanced gynecological cancer.', Journal of Clinical Oncology, 35, pp. e18024 - e18024, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e18024

Back to profile page